Taiwanese scientists have created the first genetic treatment approved by the EU for L-amino acid decarboxylase (AADC) deficiency, an extremely rare and fatal disorder, they said yesterday.
The treatment, given the trade name Upstaza, was on Wednesday approved for market by the European Medicines Agency, the EU’s main drug regulator, the National Taiwan University Hospital-based research team told a news conference.
AADC deficiency inhibits the secretion of an enzyme that is key to making dopamine, said team leader Hu Wu-liang (胡務亮), who is also the director of the hospital’s pediatrics and genetic medicine departments.
Photo: Yang Yuan-ting, Taipei Times
The disorder primarily manifests in infants and severely impedes their ability to develop speech, walk, sleep or swallow food, with death typically occurring before the age of five, he said.
The condition affects about 700 children in Taiwan, comprising 30 percent of the world’s AADC cases, suggesting that the genetic trait causing the disorder has a strong regional prevalence, Hu said.
As cases are rare in North America and Europe, where most of the world’s drugs are made, there was a lack of impetus among Western drugmakers to develop a treatment for the condition, he said.
In response, Hu launched an initiative to find a cure, and received the university hospital’s approval in his effort, which led to the creation of Upstaza in 2010, he said.
Upstaza is a one-time treatment that introduces a functioning AADC gene to the patient by directly injecting it into the patient’s brain, using modified adeno-associated viruses as the vehicle mechanism, Hu said.
An affected person with the replaced AADC gene would gain the ability to produce dopamine, leading to a partial recovery of bodily functions and providing hope for a normal life, Hu said, adding that the therapy has been proven by a 12-year tracking study.
A two-year-old patient who had been bedridden and unable to speak gained the ability to run, use staircases unassisted and verbally communicate within four years of receiving the treatment, he said.
“Using the technology, the hospital successfully treated the 30 Taiwanese patients [with AADC] to bring hope to their families,” Hu said.
The rights to the drug have been transferred to US-based PTC Therapeutics, which is exploring the possibility of applying Upstaza’s underlying viral and surgical technology to treat other conditions affecting the brain, he said.
Upstaza cannot be used for Parkinson’s disease, as the treatment requires intact neurons to work, Hu added.
ANOTHER EMERGES: The CWA yesterday said this year’s fourth storm of the typhoon season had formed in the South China Sea, but was not expected to affect Taiwan Tropical Storm Gaemi has intensified slightly as it heads toward Taiwan, where it is expected to affect the country in the coming days, the Central Weather Administration (CWA) said yesterday. As of 8am yesterday, the 120km-radius storm was 800km southeast of Oluanpi (鵝鑾鼻), Taiwan’s southernmost tip, moving at 9kph northwest, the agency said. A sea warning for Gaemi could be issued tonight at the earliest, it said, adding that the storm is projected to be closest to Taiwan on Wednesday or Thursday. Gaemi’s potential effect on Taiwan remains unclear, as that would depend on its direction, radius and intensity, forecasters said. Former Weather Forecast
As COVID-19 cases in Japan have been increasing for 10 consecutive weeks, people should get vaccinated before visiting the nation, the Centers for Disease Control (CDC) said. The centers reported 773 hospitalizations and 124 deaths related to COVID-19 in Taiwan last week. CDC Epidemic Intelligence Center Director Guo Hung-wei (郭宏偉) on Tuesday said the number of weekly COVID-19 cases reported in Japan has been increasing since mid-May and surpassed 55,000 cases from July 8 to July 14. The average number of COVID-19 patients at Japan’s healthcare facilities that week was also 1.39 times that of the week before and KP.3 is the dominant
The Chinese Communist Party’s (CCP) working group for Taiwan-related policies is likely to be upgraded to a committee-level body, a report commissioned by the Mainland Affairs Council (MAC) said. As Chinese President Xi Jinping (習近平) is increasingly likely to upgrade the CCP’s Central Leading Group for Taiwan Affairs, Taiwanese authorities should prepare by researching Xi and the CCP, the report said. At the third plenary session of the 20th Central Committee of the CCP, which ended on Thursday last week, the party set a target of 2029 for the completion of some tasks, meaning that Xi is likely preparing to
US-CHINA TRADE DISPUTE: Despite Beijing’s offer of preferential treatment, the lure of China has dimmed as Taiwanese and international investors move out Japan and the US have become the favored destinations for Taiwanese graduates as China’s attraction has waned over the years, the Ministry of Labor said. According to the ministry’s latest income and employment advisory published this month, 3,215 Taiwanese university graduates from the class of 2020 went to Japan, surpassing for the first time the 2,881 graduates who went to China. A total of 2,300 graduates from the class of 2021 went to the US, compared with the 2,262 who went to China, the document showed. The trend continued for the class of 2023, of whom 1,460 went to Japan, 1,334 went to